Last reviewed · How we verify
NCT05108181: MT-ST
Muscle Typology and Strength Training Adaptations
NA trial testing Muscle typology + exercise training in Muscle Fiber Type in 60 participants. Completed in 8 December 2023.
8 December 2023
Quick facts
| Lead sponsor | University Ghent |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 60 |
| Start date | 9 September 2021 |
| Primary completion | 8 December 2023 |
| Estimated completion | 8 December 2023 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- Muscle typology + exercise training
- Muscle typology + training frequency
Conditions studied
- Muscle Fiber Type — all drugs for Muscle Fiber Type →
- Exercise — all drugs for Exercise →
- Training Frequency — all drugs for Training Frequency →
Sponsor
University Ghent
Who can join
Adults 18 to 45, any sex, with Muscle Fiber Type or Exercise. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall aim of this project is to investigate if the responsiveness to chronic resistance training is dependent on the muscle typology. In a second aim we will investigate the most optimal training frequency for slow-twitchers and fast-twitchers. For the latter we hypothesize that slow-twitchers might cope better with higher frequencies and higher volumes compared to fast-twitchers. Male and female adult participants (18-45y) will be recruited. The subjects' muscle typology will be non-invasively estimated in the leg muscles by measurement of muscle carnosine using H-MRS. In total 21 subjects (11 slow and 10 fast subjects) will participate. Subjects will be assigned to a whole-body resistance training exercise protocol of 9 weeks in wich arm A and leg A will train 3 times per week and arm B and leg B will train 2 times per week. Before and following the training period, subjects will be subjected to different measurements (fitness level, muscle volume, strength tests, blood sampling, muscle biopsies).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Immune checkpoint blockade in cancer: current insights and future horizons.
Saman H, Makni-Maalej K, El-Ella DMA, Al-Tamimi MY, et al · · 2026 · PMID 41483376 · DOI 10.1007/s12672-025-04361-7
Verify or expand the search:
- PubMed search for NCT05108181
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Ghent trials
Trials by the same sponsor.
- NCT07398053 — General Practitioner & Pharmacist Support for Discontinuing Long-term Antidepressants in Clinically Stable Patients · NA · not yet recruiting
- NCT07343258 — Pilot Study on Follow-Up of (Acutely) Suicidal Individuals From the Flemish Suicide Helpline · NA · recruiting
- NCT07091071 — Evaluation of the CochSyn Device in Clinical Practice · NA · completed
- NCT07259408 — Co-creation of Tools for People in Detention With Suicidal Thoughts and/or Behavior · recruiting
- NCT07176156 — Evaluation of the Quality of Chat Conversations With the Suicide Helpline Zelfmoordlijn 1813 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05108181 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Ghent
- Last refreshed: 12 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05108181.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing